Humanigen Inc. [HGEN] Revenue clocked in at $4.10 million, down -90.24% YTD: What’s Next?

Humanigen Inc. [NASDAQ: HGEN] closed the trading session at $0.36 on 08/12/22. The day’s price range saw the stock hit a low of $0.363, while the highest price level was $0.3857. The company report on August 12, 2022 that Humanigen Reports Second Quarter 2022 Financial Results.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.

“We have made excellent progress on the strategic realignment announced in July. We have increased the number of sites for the PREACH-M study in Australia of lenzilumab in chronic myelomonocytic leukemia (‘CMML’), a rare blood cancer, and have interest from top oncology centers in the United States. We are on track to enroll the first patient in the RATinG study in the UK of lenzilumab in acute graft versus host disease (‘aGvHD’) and expect dosing soon,” stated Cameron Durrant, Chairman and Chief Executive Officer, Humanigen. “Given the positive results from the company’s LIVE-AIR study and the survival trend observed in the ACTIV-5/BET-B study, we have interest from a global group of leading institutions and research networks to include lenzilumab in their large-scale, multinational studies of COVID-19. Tocilizumab and baricitinib demonstrated mortality benefit following inclusion in such studies despite having failed to do so in smaller studies. We are exploring the requirements for inclusion in these studies and plan to provide an update before the end of 2022. In addition, we are currently assessing requests for investigator-initiated trials (‘IIT’s’) of lenzilumab in combination with CAR-T therapies and plan to continue the development of ifabotuzumab (‘iFab’), an EpAh-3 targeted monoclonal antibody currently in Phase 1 development, as part of an antibody drug conjugate (‘ADC’), for certain solid tumors in Australia.”.

The stocks have a year to date performance of -90.24 percent and weekly performance of -9.25 percent. The stock has been moved at -81.38 percent over the last six months. The stock has performed -28.54 percent around the most recent 30 days and changed -80.27 percent over the most recent 3-months.

If compared to the average trading volume of 7.75M shares, HGEN reached to a volume of 10080518 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Humanigen Inc. [HGEN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HGEN shares is $3.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HGEN stock is a recommendation set at 3.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Humanigen Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 13, 2022. The new note on the price target was released on July 13, 2022, representing the official price target for Humanigen Inc. stock. Previously, the target price had yet another drop from $30 to $2, while Cantor Fitzgerald kept a Neutral rating on HGEN stock.

The Average True Range (ATR) for Humanigen Inc. is set at 0.15, with the Price to Sales ratio for HGEN stock in the period of the last 12 months amounting to 6.39.

HGEN stock trade performance evaluation

Humanigen Inc. [HGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.25. With this latest performance, HGEN shares dropped by -28.54% in over the last four-week period, additionally sinking by -81.38% over the last 6 months – not to mention a drop of -97.93% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HGEN stock in for the last two-week period is set at 30.68, with the RSI for the last a single of trading hit 28.59, and the three-weeks RSI is set at 33.24 for Humanigen Inc. [HGEN]. The present Moving Average for the last 50 days of trading for this stock 1.4382, while it was recorded at 0.3658 for the last single week of trading, and 2.9564 for the last 200 days.

Humanigen Inc. [HGEN]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Humanigen Inc. [HGEN] shares currently have an operating margin of -6474.88. Humanigen Inc.’s Net Margin is presently recorded at -6582.73.

Return on Equity for this stock declined to -2,165.43, with Return on Assets sitting at -339.62.

Humanigen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.60.

Earnings per share (EPS) analysis for Humanigen Inc. [HGEN] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HGEN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Humanigen Inc. go to 12.50%.

Humanigen Inc. [HGEN]: Insider Ownership positions

There are presently around $9 million, or 40.30% of HGEN stock, in the hands of institutional investors. The top three institutional holders of HGEN stocks are: VALIANT CAPITAL MANAGEMENT, L.P. with ownership of 6,888,607, which is approximately 0% of the company’s market cap and around 20.17% of the total institutional ownership; MURCHINSON LTD., holding 5,250,000 shares of the stock with an approximate value of $1.91 million in HGEN stocks shares; and VANGUARD GROUP INC, currently with $0.89 million in HGEN stock with ownership of nearly 1.062% of the company’s market capitalization.

Positions in Humanigen Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 27 institutional holders increased their position in Humanigen Inc. [NASDAQ:HGEN] by around 2,428,383 shares. Additionally, 59 investors decreased positions by around 8,104,180 shares, while 15 investors held positions by with 14,284,060 shares. The mentioned changes placed institutional holdings at 24,816,623 shares, according to the latest SEC report filing. HGEN stock had 12 new institutional investments in for a total of 490,746 shares, while 30 institutional investors sold positions of 2,769,859 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here